0001209191-21-010208.txt : 20210212 0001209191-21-010208.hdr.sgml : 20210212 20210212170304 ACCESSION NUMBER: 0001209191-21-010208 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210210 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ostertag Eric CENTRAL INDEX KEY: 0001765987 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 21629172 MAIL ADDRESS: STREET 1: C/O POSEIDA THERAPEUTICS, INC. STREET 2: 4242 CAMPUS POINT COURT, SUITE 700 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472846548 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-10 0 0001661460 Poseida Therapeutics, Inc. PSTX 0001765987 Ostertag Eric C/O POSEIDA THERAPEUTICS, INC. 9390 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 1 1 1 0 Chief Executive Officer Common Stock 2021-02-10 4 M 0 67534 1.29 A 431590 D Common Stock 2021-02-10 4 S 0 12389 10.00 D 333845 I See footnote Common Stock 629194 I See footnote Common Stock 3972217 I See footnote Common Stock 3645111 I See footnote Common Stock 961445 I See footnote Employee Stock Option (Right to Buy) 1.29 2021-02-10 4 M 0 67534 0.00 D 2026-02-28 Common Stock 67534 0 D The sales reported in this Form 4 were effected by Transposagen Biopharmaceuticals, Inc. ("Transposagen") pursuant to a Rule 10b5-1 trading plan established independently of Dr. Ostertag and in connection with a planned dissolution of Transposagen. Dr. Ostertag reports beneficial ownership of the shares held by Transposagen as a result of his affiliation with that entity. The shares are held in the name of Transposagen, of which Dr. Ostertag is a majority stockholder. The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person. The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee. The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person is a Trustee. The reporting person's minor daughter is the sole beneficiary of the Trust. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee. The stock option is fully vested and exercisable. /s/ Johanna Mylet, Attorney-in-Fact 2021-02-12